- Home
- RFI vs DRTS Comparison
RFI vs DRTS Comparison
Compare RFI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- DRTS
- Stock Information
- Founded
- RFI 1992
- DRTS 2015
- Country
- RFI United States
- DRTS Israel
- Employees
- RFI N/A
- DRTS N/A
- Industry
- RFI Investment Managers
- DRTS Medical/Dental Instruments
- Sector
- RFI Finance
- DRTS Health Care
- Exchange
- RFI Nasdaq
- DRTS Nasdaq
- Market Cap
- RFI 313.7M
- DRTS 300.2M
- IPO Year
- RFI N/A
- DRTS N/A
- Fundamental
- Price
- RFI $11.14
- DRTS $3.51
- Analyst Decision
- RFI
- DRTS Strong Buy
- Analyst Count
- RFI 0
- DRTS 1
- Target Price
- RFI N/A
- DRTS $9.00
- AVG Volume (30 Days)
- RFI 69.8K
- DRTS 61.3K
- Earning Date
- RFI 01-01-0001
- DRTS 11-20-2025
- Dividend Yield
- RFI 8.25%
- DRTS N/A
- EPS Growth
- RFI N/A
- DRTS N/A
- EPS
- RFI N/A
- DRTS N/A
- Revenue
- RFI N/A
- DRTS N/A
- Revenue This Year
- RFI N/A
- DRTS N/A
- Revenue Next Year
- RFI N/A
- DRTS N/A
- P/E Ratio
- RFI N/A
- DRTS N/A
- Revenue Growth
- RFI N/A
- DRTS N/A
- 52 Week Low
- RFI $9.62
- DRTS $2.20
- 52 Week High
- RFI $12.52
- DRTS $4.69
- Technical
- Relative Strength Index (RSI)
- RFI 26.88
- DRTS 36.21
- Support Level
- RFI $11.40
- DRTS $3.75
- Resistance Level
- RFI $11.68
- DRTS $4.07
- Average True Range (ATR)
- RFI 0.13
- DRTS 0.19
- MACD
- RFI -0.03
- DRTS -0.05
- Stochastic Oscillator
- RFI 5.78
- DRTS 1.54
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.